10,000 Shares in Humacyte, Inc. (NASDAQ:HUMA) Bought by Petros Family Wealth LLC

Petros Family Wealth LLC acquired a new stake in Humacyte, Inc. (NASDAQ:HUMA) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $50,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Endowment Wealth Management Inc. grew its holdings in shares of Humacyte by 3.6% in the 4th quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock valued at $526,000 after buying an additional 3,590 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Humacyte by 18.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock worth $138,000 after acquiring an additional 4,327 shares in the last quarter. Rhumbline Advisers grew its stake in Humacyte by 4.6% in the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after acquiring an additional 5,005 shares during the period. Teacher Retirement System of Texas increased its holdings in shares of Humacyte by 25.3% in the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock worth $132,000 after acquiring an additional 5,293 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Humacyte by 22.0% during the fourth quarter. SG Americas Securities LLC now owns 39,143 shares of the company’s stock worth $198,000 after purchasing an additional 7,069 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

Insider Activity at Humacyte

In related news, Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction that occurred on Tuesday, April 8th. The stock was purchased at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now owns 91,207 shares of the company’s stock, valued at approximately $120,393.24. This trade represents a 121.34 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

HUMA has been the subject of several research analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Wednesday, March 26th. Benchmark reiterated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $13.71.

Humacyte Stock Down 2.5 %

Shares of HUMA opened at $1.53 on Friday. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $9.97. The stock has a market capitalization of $221.61 million, a P/E ratio of -1.14 and a beta of 1.62. The company has a 50 day moving average of $2.87 and a 200-day moving average of $4.17.

Humacyte (NASDAQ:HUMA) last released its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $7.23 million during the quarter, compared to the consensus estimate of $0.64 million. On average, sell-side analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.